LUNG - Pulmonx Corp Stock Price, Fair Value and News

7.52USD+0.02 (+0.27%)Market Closed

Market Summary

USD7.52+0.02

Market Closed

0.27%

LUNG Stock Price

View Fullscreen

LUNG RSI Chart

LUNG Valuation

Market Cap

289.0M

Price/Earnings (Trailing)

-4.75

Price/Sales (Trailing)

4.21

EV/EBITDA

-4.22

Price/Free Cashflow

-7.52

LUNG Price/Sales (Trailing)

LUNG Profitability

Operating Margin

100.00%

EBT Margin

-87.76%

Return on Equity

-51.42%

Return on Assets

-34.22%

Free Cashflow Yield

-13.29%

LUNG Fundamentals

LUNG Revenue

Revenue (TTM)

68.7M

Rev. Growth (Yr)

24.98%

Rev. Growth (Qtr)

9.11%

LUNG Earnings

Earnings (TTM)

-60.8M

Earnings Growth (Yr)

2.77%

Earnings Growth (Qtr)

6.79%

Breaking Down LUNG Revenue

Last 7 days

1.1%

Last 30 days

-18.6%

Last 90 days

-43.1%

Trailing 12 Months

-39.5%

How does LUNG drawdown profile look like?

LUNG Financial Health

Current Ratio

6.5

Debt/Equity

0.3

Debt/Cashflow

-1.07

LUNG Investor Care

Shares Dilution (1Y)

2.36%

Diluted EPS (TTM)

-1.6

Historical Charts for Stock Metrics

Get all data in R, Python etc through our Historical Stock Data APIs

Net sales

Year	Q1	Q2	Q3	Q4
2023	57.4M	60.7M	64.8M	68.7M
2022	50.0M	51.7M	51.9M	53.7M
2021	33.4M	41.9M	44.5M	48.4M
2020	35.4M	31.7M	33.3M	32.7M
2019	23.2M	26.3M	29.4M	32.6M
2018	0	0	0	20.0M

Get all data in R, Python etc through our Historical Stock Data APIs

Tracking the Latest Insider Buys and Sells of Pulmonx Corp

Filter Transactions

Datesorted ascending	Name	Buy/Sell	$ Value	Avg. Price	# Shares	Title
Mar 22, 2024	rose geoffrey beran	sold	-11,082	9.36	-1,184	chief commercial officer
Mar 15, 2024	williamson steven s.	acquired	-	-	205,286	president and ceo
Mar 01, 2024	lehman david aaron	acquired	-	-	34,500	general counsel
Mar 01, 2024	rose geoffrey beran	sold	-28,058	9.06	-3,097	chief commercial officer
Mar 01, 2024	french glendon e. iii	sold	-63,003	9.06	-6,954	president and ceo
Mar 01, 2024	lehman david aaron	acquired	-	-	69,100	general counsel
Mar 01, 2024	rose geoffrey beran	acquired	-	-	34,500	chief commercial officer
Mar 01, 2024	rose geoffrey beran	acquired	-	-	69,100	chief commercial officer
Mar 01, 2024	mckune john	acquired	-	-	14,400	interim cfo
Mar 01, 2024	mckune john	acquired	-	-	28,800	interim cfo

Which funds bought or sold LUNG recently?

View All Details

Datesorted ascending	Fund Name	Type	% Chg	$ Change	$ Held	% Portfolio
Apr 23, 2024	AMALGAMATED BANK	reduced	-76.92	-55,000	11,000	-%
Apr 22, 2024	MetLife Investment Management, LLC	unchanged	-	48,949	257,894	-%
Apr 22, 2024	CKW FINANCIAL GROUP	unchanged	-	-2,000	5,000	-%
Apr 19, 2024	VALLEY NATIONAL ADVISERS INC	new	-	9,000	9,000	-%
Apr 18, 2024	Capital Advisors, Ltd. LLC	unchanged	-	-	1,000	-%
Apr 18, 2024	Allspring Global Investments Holdings, LLC	added	609	63,643	78,943	-%
Apr 15, 2024	CFM WEALTH PARTNERS LLC	unchanged	-	-918,855	2,447,640	0.49%
Apr 05, 2024	CWM, LLC	reduced	-9.86	-	1,000	-%
Mar 22, 2024	PNC FINANCIAL SERVICES GROUP, INC.	unchanged	-	83.00	434	-%
Mar 11, 2024	VANGUARD GROUP INC	added	2.11	5,440,910	26,347,100	-%

Are Funds Buying or Selling LUNG?

Are funds buying LUNG calls or puts?

Calls

Puts

No. of funds holding Calls - Puts

Net Call Options

No. of funds that own LUNG

No. of Funds

Unveiling Pulmonx Corp's Major ShareHolders

Date Filed	Name of Filer	Percent of Class	No. of Shares	Form Type
Mar 11, 2024	fmr llc	-	0	SC 13G/A
Feb 29, 2024	point72 asset management, l.p.	5.0%	1,913,561	SC 13G
Feb 14, 2024	point72 asset management, l.p.	4.0%	1,546,089	SC 13G/A
Feb 13, 2024	vanguard group inc	5.39%	2,066,442	SC 13G/A
Feb 13, 2024	champlain investment partners, llc	0.00%	0	SC 13G/A
Feb 12, 2024	primecap management co/ca/	14.74%	5,646,451	SC 13G/A
Feb 12, 2024	flynn james e	0.02%	6,009	SC 13G/A
Feb 09, 2024	morgan stanley	5.4%	2,061,758	SC 13G/A
Feb 09, 2024	fmr llc	-	0	SC 13G
Jan 25, 2024	blackrock inc.	8.1%	3,117,063	SC 13G/A

Recent SEC filings of Pulmonx Corp

View All Filings

Date Filed	Form Type	Document
Apr 22, 2024	144	Notice of Insider Sale Intent
Apr 09, 2024	3	Insider Trading
Apr 05, 2024	ARS	ARS
Apr 05, 2024	DEF 14A	DEF 14A
Apr 05, 2024	DEFA14A	DEFA14A
Apr 02, 2024	8-K	Current Report
Mar 26, 2024	4	Insider Trading
Mar 22, 2024	144	Notice of Insider Sale Intent
Mar 19, 2024	4	Insider Trading
Mar 19, 2024	3	Insider Trading

Peers (Alternatives to Pulmonx Corp)

Name	Mkt Capsorted ascending	Revenue	Price %, 1M	Returns, 1Y	P/E	P/S	Rev 1-Yr	Inc 1-Yr
LARGE-CAP
ABT	186.7B	40.1B	-2.69%	-2.54%	32.62	4.65	-8.12%	-17.45%
BDX	67.7B	19.5B	-4.86%	-10.59%	53.89	3.47	4.02%	-22.04%
ALGN	23.4B	3.9B	-2.36%	-14.10%	52.63	6.06	3.42%	23.09%
BAX	20.8B	14.8B	-2.22%	-9.67%	7.84	1.41	2.12%	209.17%
MID-CAP
HSIC	9.4B	12.3B	-0.49%	-14.47%	22.48	0.76	-2.44%	-22.68%
ATR	9.3B	3.5B	-1.02%	16.40%	32.52	2.65	4.97%	18.89%
BIO	8.3B	2.7B	-18.63%	-38.25%	-13.07	3.12	-4.68%	82.43%
XRAY	6.4B	4.0B	-5.77%	-25.53%	-47.58	1.61	1.10%	85.84%
AXNX	3.4B	366.4M	-2.62%	10.65%	-558.61	9.25	33.86%	89.83%
PDCO	2.3B	6.6B	-4.73%	-4.84%	12.02	0.35	2.78%	-0.87%
SMALL-CAP
AHCO	1.3B	3.2B	-11.22%	-19.13%	-1.92	0.41	7.73%	-1066.14%
ANIK	383.0M	166.7M	1.30%	-3.37%	-4.63	2.3	6.67%	-456.34%
ANGO	241.5M	324.0M	12.50%	-31.24%	-1.26	0.75	-3.19%	-337.41%
APYX	45.7M	52.3M	5.60%	-56.15%	-2.44	0.87	17.61%	19.28%
AEMD	4.0M	3.7M	-11.70%	184.91%	-0.32	1.06	5.77%	8.23%

Pulmonx Corp News

Latest updates

Pulmonx Corp Earnings Report: Key Takeaways & Analysis

Income Statement (Last 12 Months)

(*) denotes actual numbers (not divided by Thousands)
Income Statement (Quarterly)																					(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2019Q2	2019Q1	2018Q4
Revenue	9.1%	19,278,000	17,668,000	17,194,000	14,535,000	15,425,000	13,502,000	13,950,000	10,785,000	13,708,000	13,261,000	12,203,000	9,244,000	9,830,000	10,612,000	3,673,000	8,618,000	10,347,000	9,104,000	7,366,000	5,778,000	-
Gross Profit	10.5%	14,400,000	13,029,000	12,734,000	10,589,000	11,184,000	10,152,000	10,418,000	8,111,000	10,251,000	9,739,000	9,029,000	6,611,000	7,078,000	7,462,000	1,012,000	5,650,000	7,337,000	6,407,000	4,953,000	3,717,000	-
Operating Expenses	0.4%	28,319,500	28,205,000	29,173,000	26,989,000	25,811,000	24,083,000	24,829,000	23,779,000	22,617,000	19,501,000	21,711,000	19,105,000	16,432,000	12,810,000	12,538,000	11,754,000	-	10,020,000	-	-	-
S&GA Expenses	1.8%	24,423,000	23,985,000	23,463,000	22,736,000	21,908,000	19,717,000	21,235,000	20,245,000	18,909,000	16,686,000	18,205,000	16,071,000	13,960,000	10,813,000	11,112,000	10,189,000	-	8,621,000	-	-	-
R&D Expenses	-7.7%	3,896,500	4,220,000	5,710,000	4,253,000	3,903,000	4,366,000	3,594,000	3,534,000	3,708,000	2,815,000	3,506,000	3,034,000	2,472,000	1,997,000	1,426,000	1,565,000	-	1,399,000	-	-	-
EBITDA Margin	7.1%	-0.83	-0.89	-0.95	-0.99	-1.07	-1.09	-1.01	-1.02	-0.98	-0.98	-0.87	-1.04	-	-	-	-	-	-	-	-	-
Interest Expenses	1.3%	904,500	893,000	864,000	571,000	359,000	286,000	223,000	198,000	199,000	207,000	206,000	217,000	267,000	1,103,000	912,000	899,000	-	460,000	-	-	-
Income Taxes	151.0%	251,000	100,000	140,000	100,000	233,000	-	40,000	100,000	135,500	44,000	80,000	100,000	-1,000	49,000	100,000	87,000	-	89,000	-	-	-
Earnings Before Taxes	8.1%	-13,640,000	-14,841,000	-16,055,000	-15,736,000	-14,037,000	-14,172,000	-14,600,000	-15,761,000	-12,854,000	-10,137,000	-12,882,000	-12,445,000	-9,276,000	-3,811,000	-11,855,000	-7,076,000	-	-4,246,000	-	-	-
EBT Margin	6.2%	-0.88	-0.94	-0.99	-1.02	-1.09	-1.10	-1.03	-1.03	-1.00	-1.00	-0.92	-1.12	-	-	-	-	-	-	-	-	-
Net Income	6.8%	-13,888,000	-14,900,000	-16,195,000	-15,860,000	-14,283,000	-14,172,000	-14,640,000	-15,828,000	-13,006,000	-10,181,000	-12,962,000	-12,512,000	-9,297,000	-3,860,000	-11,911,000	-7,163,000	-4,669,000	-4,335,000	-5,571,000	-6,128,000	-
Net Income Margin	6.2%	-0.89	-0.94	-1.00	-1.03	-1.10	-1.11	-1.04	-1.04	-1.01	-1.01	-0.92	-1.13	-	-	-	-	-	-	-	-	-
Free Cashflow	6.3%	-8,610,000	-9,192,000	-7,989,000	-12,661,000	-9,959,000	-10,979,000	-9,873,000	-15,590,000	-11,836,000	-9,958,000	-13,351,000	-9,914,000	-	-	-	-	-	-	-	-	-

Balance Sheet

(In Millions)

(*) denotes actual numbers (not divided by Millions)
Balance Sheet															(In Millions)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2019Q4
Assets	-3.9%	178	185	193	201	194	202	213	223	235	247	249	255	264	71.00	54.00
Current Assets	2.1%	150	147	164	181	169	183	193	201	208	228	233	239	250	56.00	41.00
Cash Equivalents	-12.0%	84.00	95.00	102	110	102	112	122	129	149	188	199	209	232	40.00	15.00
Inventory	3.8%	17.00	16.00	16.00	16.00	15.00	16.00	19.00	18.00	16.00	15.00	13.00	12.00	11.00	9.00	6.00
Net PPE	-0.9%	4.00	4.00	4.00	4.00	5.00	5.00	5.00	5.00	5.00	5.00	3.00	2.00	1.00	1.00	1.00
Goodwill	0%	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00	2.00
Liabilities	0.3%	59.00	59.00	59.00	57.00	40.00	39.00	41.00	41.00	42.00	44.00	40.00	39.00	38.00	71.00	36.00
Current Liabilities	13.0%	23.00	20.00	20.00	17.00	18.00	22.00	20.00	18.00	18.00	22.00	17.00	14.00	13.00	15.00	14.00
Short Term Borrowings	2268.1%	2.00	0.00	0.00	0.00	0.00	5.00	3.00	1.00	0.00	-	-	-	-	-	-
Long Term Debt	-5.6%	35.00	37.00	37.00	37.00	17.00	12.00	14.00	17.00	17.00	-	-	-	-	30.00	-
LT Debt, Current	-	-	-	-	-	-	-	-	-	-	3.00	2.00	0.00	-	-	-
LT Debt, Non Current	-5.6%	35.00	37.00	37.00	37.00	17.00	12.00	14.00	17.00	17.00	-	-	-	-	-	-
Shareholder's Equity	-5.9%	118	126	134	144	154	163	172	182	193	203	209	216	226	-	-
Retained Earnings	-3.5%	-411	-397	-382	-366	-350	-336	-321	-307	-291	-278	-268	-255	-242	-233	-210
Additional Paid-In Capital	1.1%	527	521	514	508	503	498	493	488	483	480	476	470	467	25.00	22.00
Shares Outstanding	0.6%	39.00	38.00	38.00	38.00	38.00	37.00	37.00	37.00	37.00	36.00	36.00	35.00	-	-	-
Float	-	-	-	479	-	-	-	523	-	-	-	1,200	-	-	-	-

Cashflow (Last 12 Months)

(In Thousands)

(*) denotes actual numbers (not divided by Thousands)
Cashflow (Quarterly)																			(In Thousands)
Description	(%) Q/Q	2023Q4	2023Q3	2023Q2	2023Q1	2022Q4	2022Q3	2022Q2	2022Q1	2021Q4	2021Q3	2021Q2	2021Q1	2020Q4	2020Q3	2020Q2	2020Q1	2019Q4	2019Q3	2018Q4
Cashflow From Operations	3.3%	-8,410	-8,700	-7,856	-12,644	-9,800	-10,710	-9,590	-15,000	-10,688	-8,300	-12,728	-9,672	-7,262	-5,871	-7,651	-9,849	-	-	-
Share Based Compensation	-6.7%	5,598	6,003	5,862	4,638	4,247	4,302	4,383	3,513	3,012	2,938	2,312	2,268	2,311	518	159	209	-	-	-
Cashflow From Investing	-379.1%	-2,755	987	-813	574	-727	44.00	2,080	-5,622	-29,124	-3,414	-1,186	-12,531	-693	-76.00	3,439	10,024	-	-	-
Cashflow From Financing	-97.0%	17.00	571	92.00	20,720	67.00	906	131	1,315	150	1,000	3,293	13.00	199,765	2,359	31,399	1,308	-	-	-
Buy Backs	-	-	-	-	-	27.00	-	-	-	-	-	-	26.00	-	-	-	-	-	12.00	-

LUNG Income Statement

2023-12-31

Consolidated Statements of Operations and Comprehensive Loss - USD ($) $ in Thousands	12 Months Ended
	Dec. 31, 2023	Dec. 31, 2022
Income Statement [Abstract]
Revenue	$ 68,675	$ 53,662
Cost of goods sold	17,923	13,797
Gross profit	50,752	39,865
Operating expenses
Research and development	18,080	15,397
Selling, general and administrative	94,607	83,105
Total operating expenses	112,687	98,502
Loss from operations	(61,935)	(58,637)
Interest income	5,568	1,529
Interest expense	(3,232)	(1,066)
Other income (expense), net	(673)	(396)
Net loss before tax	(60,272)	(58,570)
Income tax expense	571	353
Net loss	(60,843)	(58,923)
Other comprehensive income (loss)
Currency translation adjustment	671	150
Change in unrealized gain (losses) on marketable securities	394	(287)
Total other comprehensive income (loss)	1,065	(137)
Comprehensive loss	$ (59,778)	$ (59,060)
Net loss per share attributable to common stockholders, basic (in dollars per share)	$ (1.60)	$ (1.59)
Net loss per share attributable to common stockholders, diluted (in dollars per share)	$ (1.60)	$ (1.59)
Weighted-average shares used in computing net loss per share attributable to common stockholders, basic (in shares)	37,974,567	37,096,541
Weighted-average shares used in computing net loss per share attributable to common stockholders, diluted (in shares)	37,974,567	37,096,541

LUNG Balance Sheet

2023-12-31

Consolidated Balance Sheets - USD ($) $ in Thousands	Dec. 31, 2023	Dec. 31, 2022
Current assets
Cash and cash equivalents	$ 83,547	$ 101,736
Restricted cash	237	231
Short-term marketable securities	33,555	39,402
Accounts receivable, net	12,105	8,677
Inventory	16,743	14,564
Prepaid expenses and other current assets	4,235	4,343
Total current assets	150,422	168,953
Long-term marketable securities	14,390	5,924
Long-term inventory	2,580	5,283
Property and equipment, net	4,028	4,694
Goodwill	2,333	2,333
Intangible assets, net	31	154
Right of use assets	3,406	5,806
Other long-term assets	591	529
Total assets	177,781	193,676
Current liabilities
Accounts payable	1,497	1,758
Accrued liabilities	16,234	13,276
Income taxes payable	93	19
Deferred revenue	104	120
Short-term debt	2,155	90
Current lease liabilities	3,074	3,229
Total current liabilities	23,157	18,492
Deferred tax liability	114	94
Long-term lease liabilities	1,106	3,849
Long-term debt	35,089	17,234
Total liabilities	59,466	39,669
Commitments and contingencies (Note 8)
Stockholders’ Equity
Preferred stock, $0.001 par value, 10,000,000 shares authorized; no shares issued and outstanding as of December 31, 2023 and December 31, 2022	0	0
Common stock, $0.001 par value, 200,000,000 shares authorized; 38,516,383 shares and 37,555,565 shares issued and outstanding as of December 31, 2023 and December 31, 2022, respectively	39	38
Additional paid-in capital	526,797	502,712
Accumulated other comprehensive income	2,640	1,575
Accumulated deficit	(411,161)	(350,318)
Total stockholders’ equity	118,315	154,007
Total liabilities and stockholders’ equity	$ 177,781	$ 193,676

About Pulmonx Corp

Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. It offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. The company also provides StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. It serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. The company was incorporated in 1995 and is headquartered in Redwood City, California.

CEO	Mr. Glendon E. French
WEBSITE	https://pulmonx.com
INDUSTRY	Medical Instruments & Supplies
EMPLOYEES	269

Pulmonx Corp Frequently Asked Questions

What is the ticker symbol for Pulmonx Corp? What does LUNG stand for in stocks?

LUNG is the stock ticker symbol of Pulmonx Corp. Every public company that trades on a stock exchange gets a ticker symbol.

What is the market capital of Pulmonx Corp (LUNG)?

As of Tue Apr 23 2024, market cap of Pulmonx Corp is 289.03 Million. The market capitalization is calculated by multiplying the stock price with the number of shares outstanding.

What is the fair value of LUNG stock?

You can check LUNG's fair value in chart for subscribers.

What is the fair value of LUNG stock?

You can check LUNG's fair value in chart for subscribers. The fair value of Pulmonx Corp is provided for various growth and macro-economic scenarios from very pessimiatic to very optimistic assumptions. These fair values are estimates from Grufity's Fair Value model based on company's past performance. However, past performance of Pulmonx Corp is no guarantee of future performance. These fairvalue estimates should only be used as one of the inputs in your stock analysis. We provide model's historical fair value estimates for LUNG so that you know how good or bad the model has been in the past so you can discard it if needed. There are others that provide fair values of stocks such as wallmine, finbox, gurufocus and finviz. Most provide point in time estimates. We provide a history of our models fair value estimates so that you can get a sense of it's usefulness. Otherwise this data point is of little use.

Is Pulmonx Corp a good stock to buy?

The fair value guage provides a quick view whether LUNG is over valued or under valued. Whether Pulmonx Corp is cheap or expensive depends on the assumptions which impact Pulmonx Corp's fair value. We provide several scenarios of inflation and growth to encompass these range of assumptions for LUNG.

What is Pulmonx Corp's Price to Earnings (PE) and Price to sales (PS) ratio?

As of Tue Apr 23 2024, LUNG's PE ratio (Price to Earnings) is -4.75 and Price to Sales (PS) ratio is 4.21. The price to earnings and price to sales ratio are two most important valuation metrics for any company. PE ratio tell us the number of years of earnings investors are ready to pay for owning the company. Historically, S&P500 price to earnings ratio has fallen below 12 during periods of gloom and gone past 30 during periods of euphoria. LUNG PE ratio will change depending on the future growth rate expectations of investors.